Figure 2. MAL2 promotes breast tumor growth in immunocompetent models.

(A) Kaplan-Meier survival analysis of patients with breast cancer (BRCA) or TNBC. Patients with high versus low expression of MAL2 were compared with respect to overall survival. The overall survival data of patients in TCGA and METABRIC cohorts are combined. Log rank test was used for statistical analysis. (B–D) EO771-derived breast tumor growth in immunocompetent mice (Mal2-WT: n = 9; Mal2-OE: n = 7; and Mal2-KD: n = 7). EO771 cells with different Mal2 expression levels were orthotopically injected into female C57BL/6 mice (5 × 10⁴ cells per mouse). Tumor images (B), tumor weights (C), and tumor growth curves (D) are shown here. Data are presented as mean ± SD. One-way and 2-way ANOVA tests were used for data analysis in tumor weight and tumor growth, respectively. *P < 0.05; **P < 0.01; ***P < 0.001.